Jd Health International Inc (6618) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Jd Health International Inc stock HK$75.61, price HK$43.26, upside +74.8%, quality 74 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range HK$19.82 – HK$113.80 · fair‑value band HK$47.41 – HK$106.88 · the HK$43.26 price screens below the HK$75.61 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Jd Health International in your weekly email
Every Wednesday you see whether Jd Health International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China.
Show moreShow less
It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services.
The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions.
In addition, it provides online marketing services to advertisers; and online shopping and hospital services.
Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products.
Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services.
The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies.
JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
Stock analysis
Jd Health International Inc (6618) currently trades at HK$43.26, while our model-based Fair Value estimate is HK$75.61, implying the stock looks roughly 43% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$83.15 per share, and 16 of the 24 models we run sit above the HK$43.26 price.
Bear case: the Asset-Based group reads lowest at HK$12.83, and 8 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: HK$47.41 (bear) to HK$106.88 (bull), the price of HK$43.26 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Jd Health International Inc reported revenue of 73.4B CNY in FY2025 versus 30.7B CNY in FY2021, a compound +24.4%/yr. Reported net income was 5.4B CNY in FY2025.
Key figures
Market cap HK$139B (≈ $17.7B) Large · P/E ratio 17.8 · P/S ratio 1.30 · Net margin 7.3% · Return on equity 10.4% · Return on assets (EBIT) 0.8% (5-year average) · Operating margin 7.8% · Revenue (TTM) 79.0B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (medium confidence).
What moves the price
The share trades about 38% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 75%, 6618 screens cheaper than that median.
Fair Value models
BearHK$47.41Fair Value HK$75.61BullHK$106.88
Price HK$43.26 · Upside +74.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+26.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.1%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +61.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+61.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 5%
⚠ Approximate: the rate leans on 2025, which sits 148% above its own trend.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −9.5% a year for the price and +11.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (15 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Margin gains from supply chain efficiency and AI tools plus a shift toward higher-margin services form the main strength, while low returns, limited innovation and competitive retail dynamics remain the central weakness with no clear moat.
Main risk: New Chinese guidelines require licensed pharmacists rather than AI or other staff to review online prescriptions, which could raise operating costs and slow growth in JD Health's core pharmaceutical retail and internet hospital services.
Bull case: By deepening supply-chain efficiency and compliant AI tools for non-prescription services while expanding offline stores, JD Health could strengthen its position against rivals and adapt to tighter prescription rules.
Bear case: If stricter prescription rules raise costs significantly and Meituan plus antitrust actions erode its on-demand and platform advantages, JD Health's retail margins and user growth could come under sustained pressure.
JD Health keeps lifting margins through better supply chain efficiency and AI tools while shifting more toward higher-margin healthcare services. Yet tighter rules and rivals could still raise costs and cap growth in China's pharmacy retail space. Will the operational edge and services push add more than the pressures take away?
Compare Jd Health International Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+74.8% · Top 25%
Profitability
Return on equity (12 months)10.4% · Above median
Return on assets6.6% · Top 25%
Net margin (12 months)7.9% · Top 25%
Operating margin (12 months)7.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)15.9% · Top 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)17.8× · Cheaper than median
P/B1.96× · Pricier than median
P/S (12 months)1.49× · Priciest 25%
Price / free cash flow (fiscal year)12.1× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jd Health International Inc Fair Value". https://www.fairvalue-calculator.com/stock/6618
Frequently asked questions
Is Jd Health International Inc (6618) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of HK$75.61 versus a price of HK$43.26, about +75% upside (undervalued).
What is the fair value of 6618?
Our model-based fair value for Jd Health International Inc is HK$75.61 (as of Nov 9, 2026), built from audited fundamentals. The current price: HK$43.26.
What is the quality score of 6618?
Jd Health International Inc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jd Health International Inc (6618)?
Our model-based price target is the fair value of HK$75.61 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario HK$47.41, optimistic scenario HK$106.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Jd Health International Inc stock forecast for 2026?
Our models put fair value at HK$75.61, about +75% upside versus a price of HK$43.26 (undervalued). Cautious scenario HK$47.41, optimistic scenario HK$106.88. The calculation is refreshed regularly with new filings.
What is the revenue of Jd Health International Inc (6618)?
Jd Health International Inc reported trailing-twelve-month revenue of about 79.0B CNY (latest available figure, as of Nov 9, 2026).
What growth is priced into Jd Health International Inc (6618)?
For today's price to be fair in a discounted-cash-flow model, Jd Health International Inc would have to grow free cash flow by -8.0 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +30.5 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 6618 use?
Our models discount Jd Health International Inc at 10.3 %: a base by market capitalisation (large), damped by beta 1.19, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jd Health International Inc that is -8.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Jd Health International Inc (6618) delivered so far?
Over the past 5 years revenue at Jd Health International Inc grew +30.5 % a year. The price currently implies free-cash-flow growth of -8.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jd Health International Inc (6618) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Jd Health International Inc (-8.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jd Health International Inc (6618)?
The free-cash-flow yield on the price is 8.27 %: that much free cash flow Jd Health International Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jd Health International Inc (6618)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jd Health International Inc it is HK$75.61 per share (as of Nov 9, 2026), against a price of HK$43.26. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Jd Health International Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6618 trades below its calculated fair value: price HK$43.26, fair value HK$75.61, a gap of about +75% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6618?
No. The price is what the market pays today (HK$43.26); the fair value is what the company's own numbers justify (HK$75.61). For Jd Health International Inc the two are HK$32.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jd Health International Inc worth?
The market values Jd Health International Inc at about HK$139B (market capitalisation, as of Nov 9, 2026). Per share that is HK$43.26; our models calculate a fair value of HK$75.61 per share.
What do the bullish and bearish scenarios say about 6618?
Our models span a range for Jd Health International Inc: cautious scenario HK$47.41, base HK$75.61, optimistic HK$106.88 per share (as of Nov 9, 2026, price HK$43.26). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6618?
Jd Health International Inc trades at a price-to-earnings ratio of 17.8 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$75.61 is built from several models across several years. Other multiples: PEG 1.4, P/B 2.0, P/S 1.5, EV/EBITDA 16.9.
What is the PEG ratio of 6618?
The PEG ratio of Jd Health International Inc is 1.43 (P/E divided by earnings growth, as of Nov 9, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Jd Health International Inc (6618)?
Balance-sheet figures for Jd Health International Inc (as of Nov 9, 2026): return on equity 10.4%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 6618 from its 52-week high?
Jd Health International Inc trades at HK$43.26, about 38% below its 52-week high of HK$69.65 and 35% above the low of HK$31.98 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$75.61 is for.
Which stocks are comparable to Jd Health International Inc?
From the same area (Healthcare) we also value Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, Yixintang Pharmaceutical Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jd Health International Inc stock attractive at the current price?
The data as of Nov 9, 2026: price HK$43.26, calculated fair value HK$75.61 (+75%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6618 calculated?
We run Jd Health International Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$75.61 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Jd Health International Inc currently trades 43% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jd Health International Inc (6618)?
The closing price on Nov 6, 2026 was HK$43.26. Our model-based fair value is HK$75.61, about +75% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jd Health International Inc right now?
The price is below even our cautious bear case (HK$47.41). The market is more pessimistic than our downside scenario. Solid quality (74/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$47.41 to HK$106.88) leaves room in how you read the outcome.
Key figures of Jd Health International Inc
How large is the market capitalisation of Jd Health International Inc (6618)?
The market capitalisation of Jd Health International Inc is HK$139B (≈ $17.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jd Health International Inc (6618)?
The price-to-sales ratio of Jd Health International Inc is 1.30 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Jd Health International Inc (6618)?
The net margin of Jd Health International Inc is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jd Health International Inc (6618)?
The return on equity (ROE) of Jd Health International Inc is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jd Health International Inc (6618)?
On an EBIT basis the return on assets of Jd Health International Inc is 0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jd Health International Inc (6618)?
The operating margin of Jd Health International Inc is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jd Health International Inc (6618)?
Revenue at Jd Health International Inc is growing +15.9% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jd Health International Inc (6618)?
Earnings per share at Jd Health International Inc are growing +32.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jd Health International Inc (6618) hold?
Jd Health International Inc holds more cash than debt, 31.2B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jd Health International Inc in the live analysis
One click puts Jd Health International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026